AVROBIO (Nasdaq:AVRO) - Cours de l'action, nouvelles et analyse

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

AVRO Aperçu des actions

A clinical-stage gene therapy company, develops hematopoietic stem cell gene therapies to treat rare diseases in the United States.

A propos de l'entreprise

AVRO analyse fondamentale
Score flocon de neige
Évaluation	1/6
Croissance future	0/6
Performances passées	3/6
Santé financière	6/6
Dividendes	0/6

Récompenses

Price-To-Earnings ratio (24.9x) is below the Biotechs industry average (27.2x)

Became profitable this year

Analyse des risques

Makes less than USD$1m in revenue ($0)

Earnings are forecast to decline by an average of 18.4% per year for the next 3 years

Large one-off items impacting financial results

Does not have a meaningful market cap ($64M)

AVROBIO, Inc. Concurrents

Spero Therapeutics

NasdaqGS:SPRO

US$70.8m

Eagle Pharmaceuticals

NasdaqGM:EGRX

US$51.3m

Protalix BioTherapeutics

NYSEAM:PLX

US$77.2m

CytomX Therapeutics

NasdaqGS:CTMX

US$93.7m

Historique des prix et performances

Résumé des plus hauts, des changements et des baisses de prix pour AVROBIO
Historique des cours de bourse
Prix actuel de l'action	US$16.80
Plus haut sur 52 semaines	US$19.80
Plus bas sur 52 semaines	US$10.56
Bêta	1.22
1Variation sur 1 mois	1.45%
Variation sur 3 mois	9.38%
Variation sur 1 an	44.82%
3Variation sur 3 ans	-85.45%
Variation sur 5 ans	-90.89%
Évolution depuis l'introduction en bourse	-95.51%

Nouvelles et mises à jour récentes

Recent updates

Avrobio rises as gene therapy for Gaucher disease gets ILAP designation in UK

Oct 18

Avrobio stock rises as kidney disease gene therapy gets FDA rare pediatric disease status

Sep 20

Here's Why We're Not Too Worried About AVROBIO's (NASDAQ:AVRO) Cash Burn Situation

Mar 08

AVROBIO: Undercovered Gene Therapy Developer With Excellent Promise

Dec 25

We Think AVROBIO (NASDAQ:AVRO) Can Afford To Drive Business Growth

Nov 23

AVROBIO readies $75M equity offering

Nov 19

AVROBIO EPS misses by $0.19

Nov 05

Rendement pour les actionnaires

	AVRO	US Biotechs	US Marché
7D	-4.8%	-2.9%	0.9%
1Y	44.8%	18.9%	32.3%

Rendement vs Industrie: AVRO exceeded the US Biotechs industry which returned 6.7% over the past year.

Rendement vs marché: AVRO exceeded the US Market which returned 23.3% over the past year.

Volatilité des prix

Is AVRO's price volatile compared to industry and market?
AVRO volatility
AVRO Average Weekly Movement	5.6%
Biotechs Industry Average Movement	10.0%
Market Average Movement	6.4%
10% most volatile stocks in US Market	14.8%
10% least volatile stocks in US Market	3.2%

Cours de l'action stable: AVRO has not had significant price volatility in the past 3 months.

Volatilité au fil du temps: AVRO's weekly volatility (6%) has been stable over the past year.

À propos de l'entreprise

Fondée	Salariés	PDG	Site web
2015	13	Erik Ostrowski	www.avrobio.com

AVROBIO, Inc. Résumé des fondamentaux

Comment les bénéfices et les revenus de AVROBIO se comparent-ils à sa capitalisation boursière ?
AVRO statistiques fondamentales
Capitalisation boursière	US$63.75m
Bénéfices(TTM)	US$30.31m
Recettes(TTM)	n/a

24.9x

Ratio P/E

0.0x

Ratio P/S

Le site AVRO est-il surévalué ?

Voir Juste valeur et analyse de l'évaluation

Bénéfices et recettes

Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM)
AVRO compte de résultat (TTM)
Recettes	US$0
Coût des recettes	US$0
Marge brute	US$0
Autres dépenses	-US$30.31m
Les revenus	US$30.31m

Derniers bénéfices déclarés

Mar 31, 2024

Prochaine date de publication des résultats

s/o

Résultat par action (EPS)	0.68
Marge brute	0.00%
Marge bénéficiaire nette	0.00%
Ratio dettes/capitaux propres	0%

Quelles ont été les performances à long terme de AVRO?

Voir les performances historiques et les comparaisons

This company is no longer active

AVRO Aperçu des actions

Récompenses

Analyse des risques

AVROBIO, Inc. Concurrents

NasdaqGS:SPRO

US$70.8m

NasdaqGM:EGRX

US$51.3m

NYSEAM:PLX

US$77.2m

NasdaqGS:CTMX

US$93.7m

Historique des prix et performances

Nouvelles et mises à jour récentes

Tectonic Therapeutic, Inc. completed the acquisition of AVROBIO, Inc. (NasdaqGS:AVRO) from a group of shareholders in a reverse merger transaction.

Investor sentiment improves as stock rises 1,043%

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

New minor risk - Shareholder dilution

AVROBIO, Inc. (NasdaqGS:AVRO) entered into an agreement to acquire Tectonic Therapeutic, Inc.

Recent updates

Tectonic Therapeutic, Inc. completed the acquisition of AVROBIO, Inc. (NasdaqGS:AVRO) from a group of shareholders in a reverse merger transaction.

Investor sentiment improves as stock rises 1,043%

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

New minor risk - Shareholder dilution

AVROBIO, Inc. (NasdaqGS:AVRO) entered into an agreement to acquire Tectonic Therapeutic, Inc.

AVROBIO, Inc. (NasdaqGS:AVRO) entered into an agreement to acquire Tectonic Therapeutic, Inc.

No longer forecast to breakeven

Price target decreased by 16% to US$3.00

New major risk - Revenue and earnings growth

Chief Business Officer notifies of intention to sell stock

Novartis Pharma AG and Novartis Pharmaceuticals Corporation entered into an Asset Purchase Agreement to acquire Cystinosis Gene Therapy Program from AVROBIO, Inc. (NasdaqGS:AVRO) for $87.5 million.

Price target decreased by 8.5% to US$3.58

Novartis Pharma AG and Novartis Pharmaceuticals Corporation entered into an Asset Purchase Agreement to acquire Cystinosis Gene Therapy Program from AVROBIO, Inc. (NasdaqGS:AVRO) for $87.5 million.

Co- Founder exercised options to buy US$104k worth of stock.

AVROBIO, Inc. Announces New Positive Clinical Data and Outlines Clinical Development Plan Following Regulatory Discussions for Its Gaucher Disease Gene Therapy

Price target decreased to US$4.14

Insufficient new directors

Avrobio Receives Rare Pediatric Disease Designation from the U.S. FDA for First-In-Class Gene Therapy for Gaucher Disease

AVROBIO, Inc. Announces Completion of Patient Dosing in First Gene Therapy Clinical Trial for Cystinosis

AVROBIO, Inc. announces U.K. Medicines and Healthcare products Regulatory Agency grant an Innovation Passport under the Innovative Licensing and Access Pathway

Avrobio rises as gene therapy for Gaucher disease gets ILAP designation in UK

AVROBIO, Inc. Reports Favorable Data on Use of Combined State-Of-The-Art in Vitro Cell-Based Assays to Identify Potential Genotoxicity Risk of Integrating Vectors During Preclinical Development

AVROBIO Receives Written Notice from The Nasdaq Stock Market Regarding Minimum Bid Price Requirement

AVROBIO, Inc. Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for First Gene Therapy in Development for Cystinosis

Avrobio stock rises as kidney disease gene therapy gets FDA rare pediatric disease status

AVROBIO Inc. Announces Neuronopathic Mucopolysaccharidosis Type II or Hunter Syndrome Clinical Trial Application Accepted by U.K. Regulatory Agency to Initiate Pediatric Phase 1/2 Gene Therapy Trial

AVROBIO granted FDA’s orphan drug designation for metabolic disorder therapy

AVROBIO, Inc.(NasdaqGS:AVRO) dropped from Russell 2500 Index

AVROBIO, Inc. Announces Preclinical Data Demonstrating the Efficacy and Safety of AVR-RD-03 Gene Therapy in A Mouse Model of Infantile Onset Pompe Disease

Avrobio Reports Positive Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis, Including New Interim Data on Neurocognitive Measures

Price target decreased to US$6.29

Insufficient new directors

AVROBIO, Inc. Reports Interim Data from Phase 1/2 Clinical Trial of Investigational Gene Therapy for Cystinosis

Insufficient new directors

Insufficient new directors

AVROBIO, Inc. Announces the Appointment of Sean O’Bryan as Chief Regulatory Officer

AVROBIO, Inc. Announces New Data from Phase 2 Fab-Gt Clinical Trial Show Variable Engraftment

AVROBIO, Inc Presents Clinician Experience with FAB-GT Clinical Trial and Updated Safety Data for Investigational Gene Therapies in Fabry Disease and Gaucher Disease Type 1

Price target decreased to US$22.88

Price target increased to US$25.14

Here's Why We're Watching AVROBIO's (NASDAQ:AVRO) Cash Burn Situation

We're Keeping An Eye On AVROBIO's (NASDAQ:AVRO) Cash Burn Rate

AVROBIO, Inc.(NasdaqGS:AVRO) dropped from Russell 2500 Growth Index

AVROBIO: Fabrazyme's Full Approval Changes Things

AVROBIO, Inc. Provides Regulatory Update on Investigational AVR-RD-01 for Fabry Disease

AVROBIO, Inc. Announces Two Oral Presentations and Two Posters Featuring Data from Its Pipeline of Lysosomal Disorder Gene Therapy

Here's Why We're Not Too Worried About AVROBIO's (NASDAQ:AVRO) Cash Burn Situation

Price target lowered to US$34.50

AVROBIO, Inc. Receives Orphan Drug Designation from the European Commission for AVR-RD-04, an Investigational Gene Therapy for Cystinosis

AVROBIO, Inc. Announces 100% Kidney Substrate Reduction at 12 Months Post-Gene Therapy in First Patient Dosed with plato Gene Therapy Platform in Fabry Disease Phase 2 Trial

New 90-day high: US$17.11

Avrobio Appoints Diana M. Escolar as Chief Medical Officer

AVROBIO, Inc. Appoints Diana M. Escolar as Chief Medical Officer

AVROBIO: Undercovered Gene Therapy Developer With Excellent Promise

We Think AVROBIO (NASDAQ:AVRO) Can Afford To Drive Business Growth

AVROBIO readies $75M equity offering

AVROBIO, Inc. Avrobio Announces New Positive Clinical Data and Preclinical Data, as Well as Expanded Leading Lysosomal Disorder Gene Therapy Pipeline